Trial Profile
A Phase 2, Open-Label, Dose-Titrating Safety and Efficacy Study of QGC001 Administered Orally, Twice Daily, Over 8 Weeks in Hypertensive Overweight Subjects of Multiple Ethnic and Racial Groups in the United States
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Firibastat (Primary) ; Hydrochlorothiazide
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms NEW-HOPE
- Sponsors Quantum Genomics
- 24 Apr 2019 Results published in the Circulation
- 10 Dec 2018 Status changed from active, no longer recruiting to completed.
- 27 Nov 2018 According to a Quantum Genomics media release, results from the study will be discussed in a Key Opinion Leader (KOL) and Investor event for institutional investors and research analysts on December 10, 2018.